UroToday.com· @urotoday · X·· 4 小时前评分45
正文 · 机器翻译
在 #MIBC 中，诱导应用 Ipilimumab + Nivolumab 后联合保膀胱放化疗：INDIBLADE 2 期试验。由 Jan-Jaap Mellema @NKI_nl 报告。#ESMO26 文字报道由 @zklaassen_md > https://bit.ly/4yMMinJ #BladderCancer #Immunotherapy @myESMO
86 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.org来源：UroToday.com · x.com